Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit .NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
馬薩諸塞州牛頓市，2024年11月26日（環球新聞社）-- 博諾製藥股份有限公司。 （納斯達克：ABOS），一家臨床階段生物製藥公司，致力於開發針對毒性可溶性澱粉樣蛋白β寡聚體的新型治療藥物，用於治療阿爾茨海默病。今日宣佈，管理層將參加於2024年12月3日下午3點，在第7屆Evercore ISI HealthCONx會議上舉行的圓桌討論。
The live webcast may be accessed under the Investors tab on and will be archived for 90 days.
可在投資者選項卡下查看直播網絡廣播，並將歸檔保存90天。 ，網址爲
About Acumen Pharmaceuticals, Inc.
世銳製藥是一家臨床階段的生物製藥公司，開發一種新型治療方法，針對致毒的可溶性澱粉樣蛋白β寡聚體，治療阿爾茨海默病。世銳製藥的創始人在AβOs研究方面走在了前沿，越來越多的證據表明它們是阿爾茨海默病病理過程的早期和持續的觸發器。目前，世銳製藥專注於推進其研究產品候選Sabirnetug（ACU193）在ALTITUDE-AD（NCT06335173）的第2期臨床試驗中，治療早期症狀的阿爾茨海默病患者，經過了INTERCEPt-AD的第1期試驗的積極結果。公司總部設在馬薩諸塞州的紐頓市。
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit .
Acumen Pharmaceuticals是一家臨床階段的生物醫藥公司，正在開發一種針對阿爾茨海默病的毒性可溶性β澱粉樣寡聚體的新型治療方法。Acumen的科學創始人在β澱粉樣寡聚體的研究方面率先開展了研究，越來越多的證據表明它們是阿爾茨海默病病理的早期和持續觸發劑。Acumen目前專注於推進其研究產品候選物sabirnetug（ACU193），這是一種選擇性靶向毒性可溶性β澱粉樣寡聚體的人源單克隆抗體，正在進行的ALTITUDE-AD（NCT06335173）Phase 2臨床試驗中使用於早期症狀阿爾茨海默病患者，該試驗的Phase 1試驗INTERCEPt-AD取得了積極的結果。該公司總部位於馬薩諸塞州牛頓市。更多信息，請訪問 .
Investors:
Alex Braun
abraun@acumenpharm.com
投資者：
亞歷克斯·布勞恩
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
媒體:
AcumenPR@westwicke.com
譯文內容由第三人軟體翻譯。
